TP53 and neoplasm: The overall tumour mutation burden was low (median = 41) and mutational analysis revealed recurrently mutated genes, including TP53 (n = 5, 17.9%), ATRX (n = 3, 10.7%), and NF1 (n = 3, 10.7%), none of which were correlated with the response to treatment (Fig. 3A).